What would you do? Is it too late to develop a comprehensive community hospital cardiovascular program?

Zuckerman AM

What would you do? Should this successful integrated system divest one of its business units?

Zuckerman AM

Competitive strategy a new era.

Zuckerman AM

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators

What would you do? Are freestanding emergency centers an idea whose time has come?

Zuckerman AM

Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.

Epstein M, Leary E, Laskey R, Zuckerman A, Reed D, Lowe W

What would you do? What should this successful, growing system do with its employed physician group?

Zuckerman AM

What would you do? What should this hosipital do about its physicians developing a freestanding endoscopy unit?

Zuckerman AM

Should this healthcare system acquire a hospital in an adjacent market?

Zuckerman AM

Why children's business development?

Zuckerman AM, Markham CH

Molecular testing in the management of cardiac transplant recipients: initial clinical experience.

Starling RC, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH, Kobashigawa J, McCurry K, Marboe C, Mehra MR, Zuckerman A, Deng MC, Working Group on Molecular Testing in Cardiac Transplantation

Clobber--or collaborate? Taking a fresh look at your competition.

Zuckerman AM

Why women's health business development?

Zuckerman AM, Markham CH

Why musculoskeletal business development?

Zuckerman AM, Markham CH

Inviting lifestyles, caring people.

Zuckerman A, Zuckerman L